Barbara G Campling

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. ncbi Spontaneous smoking cessation before lung cancer diagnosis
    Barbara G Campling
    Department of Medicine, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
    J Thorac Oncol 6:517-24. 2011
  2. ncbi Clinical implication of p53 mutation in lung cancer
    Barbara G Campling
    University of Pennsylvania, School of Medicine, Clinical Research Buiding 437A, 415 Curie Blvd, Philadelphia, PA 19104, USA
    Mol Biotechnol 24:141-56. 2003
  3. ncbi Clinical implications of p53 mutations in lung cancer
    Barbara G Campling
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Methods Mol Med 75:53-77. 2003
  4. ncbi A population-based study of lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations
    Barbara G Campling
    Department of Medicine, Philadelphia Veterans Administration Medical Center, Philadelphia, PA 19104, USA
    Cancer 104:833-40. 2005
  5. ncbi The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
    M Cecilia Crisanti
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, USA
    Mol Cancer Ther 8:2221-31. 2009
  6. ncbi Clinical and molecular features of small cell lung cancer
    Allyson M Campbell
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 1:105-12. 2002

Collaborators

Detail Information

Publications6

  1. ncbi Spontaneous smoking cessation before lung cancer diagnosis
    Barbara G Campling
    Department of Medicine, Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
    J Thorac Oncol 6:517-24. 2011
    ..This led us to speculate that spontaneous smoking cessation may be a presenting symptom of lung cancer...
  2. ncbi Clinical implication of p53 mutation in lung cancer
    Barbara G Campling
    University of Pennsylvania, School of Medicine, Clinical Research Buiding 437A, 415 Curie Blvd, Philadelphia, PA 19104, USA
    Mol Biotechnol 24:141-56. 2003
    ..Novel approaches to lung cancer therapy are needed to improve the observed poor patient survival despite current therapies...
  3. ncbi Clinical implications of p53 mutations in lung cancer
    Barbara G Campling
    Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Methods Mol Med 75:53-77. 2003
    ..Preclinical and early clinical studies indicate that this is a promising approach, but clearly more effective means of gene delivery to the tumor cells are required (127-129), as discussed elsewhere in this volume...
  4. ncbi A population-based study of lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations
    Barbara G Campling
    Department of Medicine, Philadelphia Veterans Administration Medical Center, Philadelphia, PA 19104, USA
    Cancer 104:833-40. 2005
    ....
  5. ncbi The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
    M Cecilia Crisanti
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, USA
    Mol Cancer Ther 8:2221-31. 2009
    ..These studies together suggest that panobinostat may be a useful adjunct in the treatment of thoracic malignancies, especially SCLC...
  6. ncbi Clinical and molecular features of small cell lung cancer
    Allyson M Campbell
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 1:105-12. 2002
    ....